These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Treatment of depressed pregnant women by selective serotonin reuptake inhibitors: risk for the foetus and the newborn]. Favrelière S, Nourrisson A, Jaafari N, Pérault Pochat MC. Encephale; 2010 Jun; 36 Suppl 2():D133-8. PubMed ID: 20513456 [Abstract] [Full Text] [Related]
3. First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage. Bérard A, Ramos E, Rey E, Blais L, St-André M, Oraichi D. Birth Defects Res B Dev Reprod Toxicol; 2007 Feb; 80(1):18-27. PubMed ID: 17187388 [Abstract] [Full Text] [Related]
4. Paroxetine and congenital malformations: meta-Analysis and consideration of potential confounding factors. Bar-Oz B, Einarson T, Einarson A, Boskovic R, O'Brien L, Malm H, Bérard A, Koren G. Clin Ther; 2007 May; 29(5):918-926. PubMed ID: 17697910 [Abstract] [Full Text] [Related]
5. Antidepressant use during pregnancy and the risk of major congenital malformations in a cohort of depressed pregnant women: an updated analysis of the Quebec Pregnancy Cohort. Bérard A, Zhao JP, Sheehy O. BMJ Open; 2017 Jan 12; 7(1):e013372. PubMed ID: 28082367 [Abstract] [Full Text] [Related]
6. Selective serotonin reuptake inhibitor exposure during early pregnancy and the risk of fetal major malformations: focus on paroxetine. Gentile S, Bellantuono C. J Clin Psychiatry; 2009 Mar 12; 70(3):414-22. PubMed ID: 19254517 [Abstract] [Full Text] [Related]
17. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. Louik C, Lin AE, Werler MM, Hernández-Díaz S, Mitchell AA. N Engl J Med; 2007 Jun 28; 356(26):2675-83. PubMed ID: 17596601 [Abstract] [Full Text] [Related]